Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.2500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.0400/ 1
- Ask / Lots3.4200/ 5
- Open / Previous Close0.0000 / 3.2500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 926 | 3.27 |
| 09:34 ET | 300 | 3.305 |
| 09:36 ET | 723 | 3.27 |
| 09:38 ET | 729 | 3.25 |
| 09:39 ET | 317 | 3.26 |
| 09:41 ET | 164 | 3.256 |
| 09:43 ET | 100 | 3.25 |
| 09:45 ET | 400 | 3.25 |
| 09:48 ET | 2205 | 3.25 |
| 09:50 ET | 100 | 3.25 |
| 09:52 ET | 806 | 3.26 |
| 09:54 ET | 400 | 3.2501 |
| 09:57 ET | 300 | 3.25 |
| 09:59 ET | 300 | 3.255 |
| 10:01 ET | 200 | 3.25 |
| 10:08 ET | 2035 | 3.25 |
| 10:12 ET | 700 | 3.25 |
| 10:14 ET | 1000 | 3.25 |
| 10:15 ET | 400 | 3.25 |
| 10:17 ET | 7045 | 3.255 |
| 10:19 ET | 600 | 3.25 |
| 10:21 ET | 2420 | 3.245 |
| 10:26 ET | 500 | 3.25 |
| 10:28 ET | 4314 | 3.255 |
| 10:30 ET | 1492 | 3.25 |
| 10:32 ET | 4126 | 3.2501 |
| 10:33 ET | 100 | 3.25 |
| 10:35 ET | 100 | 3.25 |
| 10:37 ET | 7290 | 3.25 |
| 10:39 ET | 1533 | 3.23 |
| 10:42 ET | 10427 | 3.21 |
| 10:44 ET | 7963 | 3.19 |
| 10:46 ET | 3176 | 3.2 |
| 10:48 ET | 1836 | 3.21 |
| 10:50 ET | 1000 | 3.2 |
| 10:51 ET | 344 | 3.19 |
| 10:53 ET | 4706 | 3.19 |
| 10:55 ET | 1025 | 3.19 |
| 10:57 ET | 948 | 3.18 |
| 11:00 ET | 1070 | 3.1868 |
| 11:02 ET | 1434 | 3.185 |
| 11:04 ET | 5654 | 3.21 |
| 11:06 ET | 749 | 3.2 |
| 11:08 ET | 520 | 3.21 |
| 11:09 ET | 246 | 3.2 |
| 11:11 ET | 266 | 3.2 |
| 11:13 ET | 200 | 3.21 |
| 11:20 ET | 18888 | 3.22 |
| 11:22 ET | 1010 | 3.2299 |
| 11:24 ET | 9147 | 3.26 |
| 11:26 ET | 1878 | 3.26 |
| 11:27 ET | 500 | 3.26 |
| 11:29 ET | 1133 | 3.25 |
| 11:31 ET | 100 | 3.25 |
| 11:33 ET | 816 | 3.245 |
| 11:36 ET | 3534 | 3.23 |
| 11:38 ET | 100 | 3.225 |
| 11:40 ET | 14811 | 3.246 |
| 11:45 ET | 666 | 3.25 |
| 11:49 ET | 6072 | 3.27 |
| 11:51 ET | 2094 | 3.2805 |
| 11:54 ET | 2075 | 3.28 |
| 11:56 ET | 100 | 3.29 |
| 11:58 ET | 2088 | 3.28 |
| 12:00 ET | 506 | 3.27 |
| 12:02 ET | 100 | 3.27 |
| 12:03 ET | 105 | 3.27 |
| 12:05 ET | 100 | 3.27 |
| 12:07 ET | 1290 | 3.274 |
| 12:14 ET | 5497 | 3.26 |
| 12:16 ET | 3100 | 3.26 |
| 12:18 ET | 100 | 3.255 |
| 12:20 ET | 1684 | 3.26 |
| 12:21 ET | 13598 | 3.27 |
| 12:25 ET | 100 | 3.27 |
| 12:27 ET | 100 | 3.26 |
| 12:30 ET | 300 | 3.26 |
| 12:32 ET | 100 | 3.265 |
| 12:34 ET | 200 | 3.26 |
| 12:36 ET | 156 | 3.26 |
| 12:39 ET | 400 | 3.265 |
| 12:41 ET | 673 | 3.265 |
| 12:48 ET | 100 | 3.26 |
| 12:50 ET | 100 | 3.26 |
| 12:52 ET | 1500 | 3.265 |
| 12:56 ET | 3499 | 3.26 |
| 12:57 ET | 100 | 3.265 |
| 01:01 ET | 100 | 3.26 |
| 01:08 ET | 295 | 3.26 |
| 01:10 ET | 100 | 3.26 |
| 01:12 ET | 200 | 3.26 |
| 01:14 ET | 200 | 3.25 |
| 01:15 ET | 200 | 3.25 |
| 01:19 ET | 292 | 3.24 |
| 01:21 ET | 200 | 3.22 |
| 01:24 ET | 300 | 3.22 |
| 01:26 ET | 354 | 3.22 |
| 01:28 ET | 214 | 3.22 |
| 01:30 ET | 6750 | 3.23 |
| 01:35 ET | 300 | 3.22 |
| 01:37 ET | 211 | 3.23 |
| 01:39 ET | 100 | 3.24 |
| 01:42 ET | 550 | 3.23 |
| 01:46 ET | 300 | 3.23 |
| 01:50 ET | 978 | 3.22 |
| 01:51 ET | 1300 | 3.23 |
| 01:53 ET | 1204 | 3.235 |
| 01:55 ET | 5119 | 3.235 |
| 01:57 ET | 1609 | 3.23 |
| 02:02 ET | 500 | 3.24 |
| 02:04 ET | 400 | 3.23 |
| 02:06 ET | 1002 | 3.235 |
| 02:08 ET | 400 | 3.23 |
| 02:09 ET | 200 | 3.235 |
| 02:11 ET | 400 | 3.23 |
| 02:13 ET | 100 | 3.24 |
| 02:15 ET | 3492 | 3.25 |
| 02:20 ET | 1344 | 3.27 |
| 02:22 ET | 774 | 3.26 |
| 02:24 ET | 539 | 3.2612 |
| 02:27 ET | 300 | 3.27 |
| 02:31 ET | 523 | 3.265 |
| 02:36 ET | 100 | 3.26 |
| 02:38 ET | 200 | 3.27 |
| 02:40 ET | 300 | 3.265 |
| 02:42 ET | 940 | 3.26 |
| 02:44 ET | 302 | 3.265 |
| 02:45 ET | 200 | 3.26 |
| 02:49 ET | 3785 | 3.275 |
| 02:51 ET | 2700 | 3.27 |
| 02:54 ET | 1100 | 3.265 |
| 02:58 ET | 1557 | 3.265 |
| 03:00 ET | 100 | 3.27 |
| 03:02 ET | 400 | 3.26 |
| 03:03 ET | 100 | 3.25 |
| 03:05 ET | 506 | 3.255 |
| 03:07 ET | 116 | 3.25 |
| 03:09 ET | 310 | 3.25 |
| 03:12 ET | 102 | 3.25 |
| 03:14 ET | 300 | 3.25 |
| 03:16 ET | 211 | 3.255 |
| 03:18 ET | 421 | 3.25 |
| 03:20 ET | 200 | 3.25 |
| 03:21 ET | 100 | 3.255 |
| 03:23 ET | 439 | 3.25 |
| 03:27 ET | 200 | 3.25 |
| 03:30 ET | 116 | 3.25 |
| 03:32 ET | 2351 | 3.25 |
| 03:34 ET | 400 | 3.245 |
| 03:36 ET | 2357 | 3.245 |
| 03:38 ET | 2562 | 3.2499 |
| 03:39 ET | 2631 | 3.24 |
| 03:41 ET | 1505 | 3.245 |
| 03:43 ET | 429 | 3.245 |
| 03:45 ET | 3571 | 3.265 |
| 03:48 ET | 3198 | 3.255 |
| 03:50 ET | 300 | 3.25 |
| 03:52 ET | 1114 | 3.255 |
| 03:54 ET | 5006 | 3.26 |
| 03:56 ET | 311 | 3.26 |
| 03:57 ET | 2700 | 3.265 |
| 03:59 ET | 4547 | 3.25 |
Jun 25, 2024
Jun 20, 2024
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 193.1M | -6.4x | --- |
Rani Therapeutics Holdings Inc | 196.1M | -3.0x | --- |
Biomea Fusion Inc | 187.3M | -1.2x | --- |
Design Therapeutics Inc | 187.0M | -3.1x | --- |
Trevi Therapeutics Inc | 186.7M | -7.8x | --- |
Rezolute Inc | 205.5M | -3.5x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $193.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
